Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide

Final results from a human pilot study show DehydraTECH TM -powered semaglutide outperforms Rybelsus ® : Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug delivery; and Reduced side effects. KELONA, BC / January 4, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces positive final results from its recently completed human Pilot Study #1 (the “ Study “) evaluating DehydraTECH TM technology for the oral delivery of the glucagon-like peptide-1 (“ GLP-1 “) drug semaglutide available commercially in the branded product Rybelsus®. The Study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus ® tablet (“ Control “) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“ DehydraTECH GLP-1 “). In general, the DehydraTECH processing enabled improvements in delivery of semaglutide to the bloodstream, and the improvements in controlling blood sugar were more pronounced in the final combined results of the Study than they were in the first half of the Study as reported in press releases issued November 27 and November 28 , 2023. Blood Levels of Semaglutide The first post-baseline blood was sampled 20 minutes after oral administration and, at that point in time, the DehydraTECH GLP-1 blood semaglutide level was ~261% higher than that of the Control, demonstrating DehydraTECH’s well-known ability to deliver drugs to the bloodstream faster. At each of the 19 blood sample time points, the DehydraTECH GLP-1 blood semaglutide levels were higher than the Control levels. The peak levels of semaglutide in blood were 43% higher in the DehydraTECH GLP-1 than in the Rybelsus ® Control. Blood Semaglutide Levels (mmol/L) Rybelsus Control (blue) 7mg (n=7) DehydraTECH (orange) GLP-1 7mg (n=7) 24 hours after the ingestion of the single dose, the DehydraTECH GLP-1 blood semaglutide levels were approximately 44% higher than the Control levels (Note – only the first 10 hours post dosing is shown in the graph above). Side Effects The DehydraTECH GLP-1 processed semaglutide was generally better tolerated than the Rybelsus ® tablets themselves. Only the Rybelsus ® tablets resulted in instances of moderate nausea and moderate diarrhea, whereas no such instances were reported upon DehydraTECH-semaglutide dosing. Blood Glucose Levels It is accepted by the Food and Drug Administration (“ FDA “) that, “ one role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar) .” Because blood glucose levels are a key consideration in control of diabetes and other health conditions, the Study measured blood glucose levels at each of the 19 sample time points. Blood Glucose Levels (mmol/L) Rybelsus Control (blue) 7mg (n=7) DehydraTECH (orange) GLP-1 7mg (n=7) The Control group evidenced inconsistent blood glucose reduction that did not prevent blood glucose spikes after eating. DehydraTECH GLP-1 reduced blood glucose to lower levels and was much more effective at maintaining consistently reduced blood glucose levels even after eating a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark. Actual data levels for each hour after Rybelsus® (control) and DehydraTECH drug administration are shown below. Blood Glucose Levels (mmol/L) Minutes Control Mean Change from Time Zero DehydraTECH Mean Change from Time Zero 0 5.04 5.13 60 4.84 -3.97% 4.54 -11.42% 120 4.63 -8.22% 4.34 -15.32% 180 4.49 -11.05% 4.33 -15.60% 240 4.46 -11.61% 4.33 -15.60% 300 5.43 + 7.65% 4.60 -10.31% 360 5.39 + 6.80% 4.64 -9.47% 420 5.5 + 9.07% 4.67 -8.91% 480 5.3 + 5.10% 4.64 -9.47% 540 5.09 + 0.85% 4.60 -10.31% 600 5.03 -0.28% 4.61 -10.03% 24-Hour 5.04 0.00% 4.87 -5.01% Notably, even as long as 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 5.01% relative to baseline while the blood glucose levels evidenced in the Rybelsus® Control group were unchanged. Our current assumption is that the improved delivery of semaglutide using DehydraTECH is most likely responsible for the observed greater efficacy in achieving sustained blood glucose reduction, thereby helping to attenuate the postprandial spikes in blood glucose experienced in the Control group. This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations. There was minor variability in the diets of the subjects at the 240-minute meal and 360-minute snack intervals noted above during the concentrated 10-hour post dosing monitoring period which could account for some of the differences in the test data, although meal and snack selection allowance was from a set of standardized choices. Future Work Due to the success of the Study, Lexaria is already preparing for other human and animal studies to continue the evaluation of DehydraTECH’s effectiveness with GLP-1 drugs. This work will be conducted on an expedited basis given the urgent need for effective oral delivery of GLP-1 drugs and DehydraTECH’s apparent ability to improve their performance. Lexaria will provide more details about its GLP-1 strategy in separate news. About the Study The Study was performed to provide an early-stage indication of whether DehydraTECH processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide sold as Rybelsus ® . A single semaglutide dose of 7 mg of the Control was compared to the matching dose of the DehydraTECH GLP-1, swallowed by each subject after an overnight fasting period together with a 50 mL glass of water. The DehydraTECH GLP-1 formulation used in this Study was compound formulated strictly for research purposes. Seven healthy subjects were dosed with each test article following a cross over study design across two study visits. About Semaglutide Rybelsus ® (semaglutide) is the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic ® and Wegovy ® , administered by injection , to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk ® . About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com . CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic – Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. View the original press release on accesswire.com 0 Comments Author mmcdonald Leave a Reply Cancel reply Your email address will not be published. Comment You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Search for: Categories Press Releases 225 Recent Posts Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 9, 2026 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 8, 2026 Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference September 4, 2026 Lexaria Receives USD$2.6 Million Tax Rebate Payment September 1, 2026 DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 August 24, 2026 Archives September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. 250.765.6424 [email protected] Canadian Operations #100-740 McCurdy Road Kelowna, BC, V1X2P7 US Operations 210 Shamrock Industrial Blvd., Suite C Tyrone, GA 30290 Australia Operations C/o Lexaria (AU) Pty Ltd Suite 1 Level 3, 62 Lygon Street Carlton South, VIC 3053 Privacy Policy General Disclaimer: No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases… Read More Copyright © 2024 Lexaria Bioscience . All rights reserved.

The release as fetched from its publisher. lexariabioscience.com ↗